Dube Eric M insider trades
Dube Eric M has filed 27 Form 4s with the SEC that we hold, for Travere Therapeutics, Inc. (TVTX) (CHIEF EXECUTIVE OFFICER, Director) and OnKure Therapeutics, Inc. (RPHM) (Director). Across all of them we count 0 purchases worth $0 and 43 sales worth $58.5M reported on Form 4. In the last 12 months: 0 purchases ($0) and 24 sales ($54.5M). The largest single trade was a sale of 128,065 shares of Travere Therapeutics, Inc. worth $6.8M, dated 2026-10-15. Of 11 sales filed since we began reading the 10b5-1 checkbox, 11 (100%) were marked as made under a 10b5-1 trading plan. The first filing on our record is dated 2021-08-17 and the latest 2026-10-19.
Travere Therapeutics, Inc. (TVTX)
| Trade date | Code | Shares | Value as filed | Filed | Source |
|---|---|---|---|---|---|
| 2021-08-17 | S, sale reported on Form 4 | 7,836 | $134.2K | 2021-08-17 | SEC |
| 2022-01-04 | S, sale reported on Form 4 | 4,832 | $147.0K | 2022-01-06 | SEC |
| 2022-01-05 | S, sale reported on Form 4 | 2,139 | $65.2K | 2022-01-06 | SEC |
| 2022-01-05 | S, sale reported on Form 4 | 10,361 | $309.2K | 2022-01-06 | SEC |
| 2022-01-24 | S, sale reported on Form 4 | 7,873 | $196.7K | 2022-01-26 | SEC |
| 2022-01-31 | S, sale reported on Form 4 | 4,813 | $131.9K | 2022-02-02 | SEC |
| 2022-02-10 | S, sale reported on Form 4 | 4,832 | $134.5K | 2022-02-11 | SEC |
| 2023-01-05 | S, sale reported on Form 4 | 5,625 | $116.7K | 2023-01-06 | SEC |
| 2023-01-24 | S, sale reported on Form 4 | 6,442 | $138.5K | 2023-01-26 | SEC |
| 2023-02-01 | S, sale reported on Form 4 | 8,196 | $182.4K | 2023-02-02 | SEC |
| 2023-09-05 | S, sale reported on Form 4 | 4,455 | $65.5K | 2023-09-05 | SEC |
| 2024-01-23 | S, sale reported on Form 4 | 7,873 | $70.5K | 2024-01-25 | SEC |
| 2024-02-01 | S, sale reported on Form 4 | 10,016 | $88.7K | 2024-02-02 | SEC |
| 2024-02-01 | S, sale reported on Form 4 | 9,106 | $77.7K | 2024-02-02 | SEC |
| 2024-09-09 | S, sale reported on Form 4 | 21,125 | $243.4K | 2024-09-09 | SEC |
| 2025-01-22 | S, sale reported on Form 4 | 10,736 | $208.9K | 2025-01-23 | SEC |
| 2025-02-03 | S, sale reported on Form 4 | 50,691 | $1.0M | 2025-02-04 | SEC |
| 2025-02-11 | S, sale reported on Form 4 | 11,375 | $273.5K | 2025-02-12 | SEC |
| 2025-05-05 | S, sale reported on Form 4 | 18,924 | $398.4K | 2025-05-05 | SEC |
| 2025-10-28 | S, sale reported on Form 4 | 92,872 | $2.8M | 2025-10-30 | SEC |
| 2025-10-29 | S, sale reported on Form 4 | 27,128 | $817.1K | 2025-10-30 | SEC |
| 2026-01-23 | S, sale reported on Form 4 | 8,135 | $244.1K | 2026-01-27 | SEC |
| 2026-01-27 | S, sale reported on Form 4 | 51,865 | $1.6M | 2026-01-27 | SEC |
| 2026-02-03 | S, sale reported on Form 4 | 33,635 | $1.1M | 2026-02-03 | SEC |
| 2026-02-03 | S, sale reported on Form 4 | 66,452 | $2.1M | 2026-02-03 | SEC |
| 2026-02-20 | S, sale reported on Form 4 | 60,000 | $1.8M | 2026-02-24 | SEC |
| 2026-04-01 | S, sale reported on Form 4 | 25,098 | $789.6K | 2026-04-02 | SEC |
| 2026-04-01 | S, sale reported on Form 4 | 34,902 | $1.1M | 2026-04-02 | SEC |
| 2026-04-15 | S, sale reported on Form 4 | 56,815 | $2.3M | 2026-04-15 | SEC |
| 2026-04-15 | S, sale reported on Form 4 | 20 | $853 | 2026-04-15 | SEC |
| 2026-04-15 | S, sale reported on Form 4 | 7,165 | $299.1K | 2026-04-15 | SEC |
| 2026-05-06 | S, sale reported on Form 4 | 22,500 | $988.9K | 2026-05-06 | SEC |
| 2026-09-15 | S, sale reported on Form 4 | 63,498 | $3.9M | 2026-09-17 | SEC |
| 2026-09-15 | S, sale reported on Form 4 | 28,796 | $1.8M | 2026-09-17 | SEC |
| 2026-09-15 | S, sale reported on Form 4 | 3,102 | $197.4K | 2026-09-17 | SEC |
| 2026-09-15 | S, sale reported on Form 4 | 270 | $17.6K | 2026-09-17 | SEC |
| 2026-09-16 | S, sale reported on Form 4 | 99,716 | $6.3M | 2026-09-17 | SEC |
| 2026-09-16 | S, sale reported on Form 4 | 96,125 | $6.1M | 2026-09-17 | SEC |
| 2026-09-17 | S, sale reported on Form 4 | 101,691 | $6.6M | 2026-09-17 | SEC |
| 2026-09-17 | S, sale reported on Form 4 | 6,802 | $441.8K | 2026-09-17 | SEC |
| 2026-10-15 | S, sale reported on Form 4 | 128,065 | $6.8M | 2026-10-19 | SEC |
| 2026-10-15 | S, sale reported on Form 4 | 37,270 | $2.0M | 2026-10-19 | SEC |
| 2026-10-15 | S, sale reported on Form 4 | 78,400 | $4.3M | 2026-10-19 | SEC |
OnKure Therapeutics, Inc. (RPHM)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1763494) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
